[CommodityCoverage]

Triple Trial Momentum: Thiogenesis Therapeutics (TTI.v TTIPF) Surges on Breakthroughs in Mitochondrial & Metabolic Disease Pipeline

Targeting rare, high-need diseases like MELAS, Leigh Syndrome (in partnership with CHOP), and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is gaining serious traction as its lead candidate, TTI-0102, advances through three Phase 2 trials.

Backed by EMA guidance and growing regulatory momentum, TTI is emerging as a key player in pediatric and metabolic drug development.

Check out the full story here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/

[CommodityCoverage]

Today, Thiogenesis Therapeutics (TTI.v TTIPF) is up over 12% over 6x the average volume amid three active clinical trials for its lead candidate, TTI-0102, a prodrug designed to target mitochondrial and oxidative stress-related disorders.

Check out a breakdown of TTI's current clinical pipeline here:

Significant Clinical Pipeline Progress - @thiogenesis $TTI.v $TTIPF
June has marked a busy month for $TTI, advancing its position as a leader in mitochondrial medicine with significant clinical momentum across both sides of the Atlantic this month.$TTI has officially initiated… pic.twitter.com/rmMD4zwlV8

— Stock Master Flash (@StckMasterFlash) June 24, 2025

[CommodityCoverage]

As the FDA faces mounting delays, Thiogenesis Therapeutics (TTI.v TTIPF) is quietly making clinical strides in Europe—recently dosing its first patient in France and expanding its Phase 2 trial for MELAS, a rare and debilitating mitochondrial disease with no approved treatments:

TODAY: @thiogenesis Advances Phase 2 MELAS Trial with French Site Activation $TTI.v $TTIPF

Clinical-stage biotech company, $TTI, has activated its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS.

The first… https://t.co/ePrltPJLNY pic.twitter.com/cJ6yy3p2o0

— Stock Master Flash (@StckMasterFlash) June 17, 2025

 
With interim results expected this fall, and a novel sulfur-based therapy targeting the root causes of mitochondrial dysfunction, TTI is emerging as a biotech to watch in the high-need orphan disease space, with two other active trials currently running.

[CommodityCoverage]

Recently, Thiogenesis Therapeutics (TTI.v TTIPF) received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in patients with Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disease with no approved therapies.
 
Notably, the trial will be led by the Children’s Hospital of Philadelphia (CHOP), a world leader in pediatric mitochondrial research, underscoring the scientific credibility and clinical importance of this program.
 
The two-stage trial will assess safety, pharmacokinetics, and early efficacy of TTI-0102 in both adolescent and pediatric LSS patients, with the CHOP team—led by Drs. Zarazuela Zolkipli-Cunningham and Marni Falk—highlighting its potential to deliver meaningful clinical benefit.
 
Full News Breakdown:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

 
Posted on Behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Advancing a rare disease pipeline, Thiogenesis Therapeutics (TTI.v TTIPF) has three active clinical trials targeting mitochondrial and oxidative stress-related disorders:

1) Phase 2a Trial in Leigh Syndrome Spectrum (LSS) – Now enrolling in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care.

2) Phase 2 Trial in For MELAS – Running in Europe targeting a devastating mitochondrial disease with no approved treatments in the U.S. or EU.

3) Phase 2a Trial in MASH – Running with supportive scientific advice from the EMA and targeting highly underserved metabolic liver disease.

With growing clinical momentum and a unique sulfur-based platform, TTI is positioned at the forefront of mitochondrial medicine.

Latest News Breakdown:

TODAY: @thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe + Core Patent Granted in EU$TTI.v $TTIPF

The European Medicines Agency (EMA) has provided supportive scientific advice for $TTI's Investigational Medicinal Product… https://t.co/V2m8cM9yQz

— Stock Master Flash (@StckMasterFlash) June 25, 2025

Posted on Behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Marking the third active Phase 2 program for its novel cysteine-enhancing drug, Thiogenesis Therapeutics (TTI.v TTIPF) has receiving supportive scientific advice from the EMA to initiate a Phase 2a trial, this time targeting MASH in children, a highly underserved metabolic liver disease:

TODAY: @thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe + Core Patent Granted in EU$TTI.v $TTIPF

The European Medicines Agency (EMA) has provided supportive scientific advice for $TTI's Investigational Medicinal Product… https://t.co/V2m8cM9yQz

— Stock Master Flash (@StckMasterFlash) June 25, 2025

 
 With active trials now underway in Europe and the U.S. and patent protection locked in through 2038, TTI is quickly emerging as a clinical-stage leader in pediatric rare disease therapeutics.

[StockInfo11]

Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) shared that it received EMA support to launch a Phase 2a trial of its lead drug for pediatric MASH in Europe. A core EU patent was also granted for its cysteamine prodrug platform, securing IP protection until 2038. Full news breakdown & DD here⬇️
https://www.reddit.com/r/PennyStocksCanada/comments/1lkknd5/thiogenesis_therapeutics_ttiv_ttipf_receives_ema/

[CommodityCoverage]

Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has secured a major regulatory milestone in Europe—receiving supportive scientific advice from the EMA to initiate a Phase 2a trial of TTI-0102 in children with MASH, a serious and underserved metabolic liver disease.
 
This marks the third active Phase 2 program for TTI-0102, adding to ongoing trials for MELAS in Europe and Leigh syndrome in the U.S., and further solidifies the company’s IP and regulatory footing with new EU patent protection through 2038.
 
With multiple rare disease indications now advancing in parallel, TTI is rapidly positioning itself as a clinical-stage leader in pediatric mitochondrial and metabolic therapeutics.
 
Check out the full story here:

TODAY: @thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe + Core Patent Granted in EU$TTI.v $TTIPF

The European Medicines Agency (EMA) has provided supportive scientific advice for $TTI's Investigational Medicinal Product… https://t.co/V2m8cM9yQz

— Stock Master Flash (@StckMasterFlash) June 25, 2025

 
Posted on Behalf of Thiogenesis Therapeutics Corp.

[StockInfo11]

Thiogenesis (TTI.v TTIPF), a clinical-stage biopharmaceutical company, shared today that it has received EMA support to launch a Phase 2a trial of its lead drug for pediatric MASH and secured a core EU patent for its cysteamine prodrug tech, protecting IP to 2038. Full news here: https://www.theglobeandmail.com/investing/markets/markets-news/NewsFile/33044957/thiogenesis-receives-confirmatory-guidance-on-impd-for-pediatric-mash-phase-2a-clinical-trial-in-europe-and-core-patent-granted-in-eu/

*Posted on behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that the European Medicines Agency (EMA) has provided supportive scientific advice for Thiogenesis’ Investigational Medicinal Product Dossier (IMPD), enabling a Phase 2a clinical trial of TTI-0102 in pediatric patients with metabolic dysfunction-associated steatohepatitis (MASH): [NEWS RELEASE]

This development advances TTI-0102 as a promising therapeutic candidate across multiple pediatric mitochondrial and metabolic diseases and strengthens TTI's IP and regulatory position in Europe amid its ongoing Phase 2 trials in Europe for MELAS as well as its IND-cleared Phase 2a trial for Leigh syndrome (LSS) in the U.S.

More info on TTI's other trials:

Significant Clinical Pipeline Progress - @thiogenesis $TTI.v $TTIPF
June has marked a busy month for $TTI, advancing its position as a leader in mitochondrial medicine with significant clinical momentum across both sides of the Atlantic this month.$TTI has officially initiated… pic.twitter.com/rmMD4zwlV8

— Stock Master Flash (@StckMasterFlash) June 24, 2025

[StockInfo11]

Thiogenesis Therapeutics (TTI.v TTIPF) has expanded its Phase 2 MELAS trial of its lead drug (TTI-0102) to France, dosing the first patient at CHU Angers. Strong enrollment progress has triggered an interim analysis now planned for Sept 2025. Full update: https://www.newsfilecorp.com/release/255687/Thiogenesis-Announces-Second-Site-Begins-Enrolling-in-Phase-2-MELAS-Clinical-Trial-and-Provides-Update

*Posted on behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

June has marked a busy month for Thiogenesis Therapeutics (TTI.v TTIPF), advancing its position as a leader in mitochondrial medicine with major clinical momentum this month across both sides of the Atlantic.

TTI initiated a Phase 2a trial for Leigh Syndrome Spectrum in collaboration with the Children’s Hospital of Philadelphia (CHOP)—one of the world’s foremost centers in pediatric mitochondrial disorders:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

Simultaneously, TTI is actively dosing patients in its Phase 2 trial for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) at clinical sites across Europe:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing its lead candidate, TTI-0102, into a Phase 2a trial for Leigh Syndrome Spectrum (LSS).

Notably, this is a landmark collaboration underscores the scientific strength behind TTI’s approach and marks a major step toward addressing a critical unmet medical need, as LSS is a devastating mitochondrial disorder with no approved therapies.

Check out the full story here:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) has received FDA clearance to begin a Phase 2a trial of its lead candidate, TTI-0102, for the treatment of Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disorder with no approved therapies:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

Reflecting both the scientific credibility of Thiogenesis’ approach and the strong preclinical rationale for targeting oxidative stress in LSS patients, the trial will be held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric mitochondrial medicine.

[CommodityCoverage]

As U.S. clinical trials face growing delays, Thiogenesis Therapeutics (TTI.v TTIPF) is leveraging the EU’s more efficient framework to accelerate enrollment and generate early efficacy data, having activated its second clinical site in France for its ongoing Phase 2 trial of TTI-0102 in MELAS patients—highlighting the strategic advantage of conducting rare disease trials in Europe:

TODAY: @thiogenesis Advances Phase 2 MELAS Trial with French Site Activation $TTI.v $TTIPF

Clinical-stage biotech company, $TTI, has activated its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS.

The first… https://t.co/ePrltPJLNY pic.twitter.com/cJ6yy3p2o0

— Stock Master Flash (@StckMasterFlash) June 17, 2025

With streamlined regulatory pathways, faster site activation, and greater scientific collaboration, Europe is proving to be an increasingly attractive jurisdiction for clinical-stage biotech companies. 

Now with multiple active sites across France and the Netherlands, and interim results expected in September 2025, TTI is gaining momentum in a market known for supporting high-unmet-need orphan drug development.

Posted on Behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease:

TODAY: @thiogenesis Advances Phase 2 MELAS Trial with French Site Activation $TTI.v $TTIPF

Clinical-stage biotech company, $TTI, has activated its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS.

The first… https://t.co/ePrltPJLNY pic.twitter.com/cJ6yy3p2o0

— Stock Master Flash (@StckMasterFlash) June 17, 2025

On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA.

[CommodityCoverage]

Today, Thiogenesis Therapeutics (TTI.v TTIPF), a clinical-stage biotech, has announced the activation of its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS, marking a key expansion milestone for the multicenter European study: https://www.newsfilecorp.com/release/255687/Thiogenesis-Announces-Second-Site-Begins-Enrolling-in-Phase-2-MELAS-Clinical-Trial-and-Provides-Update

The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S."

This update follows TTI receiving FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum with the Children's Hospital of Philadelphia—a rare, life-threatening mitochondrial disorder with no approved treatments. More info:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

[CommodityCoverage]

With two Phase 2 trials now underway, one in MELAS (Europe) and a newly FDA-cleared study in Leigh Syndrome Spectrum (U.S.), Thiogenesis Therapeutics (TTI.v TTIPF) is targeting two of the most severe pediatric mitochondrial disorders with its novel cysteine-enhancing drug, TTI-0102.

Backed by top-tier institutions like CHOP and strong preclinical data, these trials represent major steps toward delivering the first disease-modifying therapy in a space with no approved treatments.

More info:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

[CommodityCoverage]

Marking a pivotal moment in affirming the scientific and clinical promise of its lead candidate, Thiogenesis Therapeutics (TTI.v TTIPF) received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

This approval is a critical endorsement, especially given the early-stage nature of the asset and the disease's high unmet need; validating TTI's approach of targeting oxidative stress via intracellular cysteine and glutathione elevation and signalling confidence in the safety and potential efficacy of TTI-0102, which is additionally in clinical trials in Europe for MELAS.

[CommodityCoverage]

Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments.

Backed by leading experts at Children’s Hospital of Philadelphia, a leader in pediatric mitochondrial medicine, serving as the lead clinical site, and strong preclinical data, the study will assess TTI-0102’s potential to reduce oxidative stress and improve quality of life for patients.

This milestone marks a major step toward addressing a critical unmet medical need and positions TTI for potential breakthrough therapy designation - in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment.

Check out the full story here:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

[CommodityCoverage]

Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that it has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum—a rare and life-threatening pediatric mitochondrial disease.

The Phase 2a clinical trial is expected to begin in H2 2025, with the Children’s Hospital of Philadelphia (CHOP), a leader in pediatric mitochondrial medicine, serving as the lead clinical site.

This trial will run in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment.

Full Breakdown Here:

TODAY: @thiogenesis Announces FDA Clearance of IND for TTI-0102 in Leigh Syndrome Spectrum $TTI.v $TTIPF$TTI has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum (LSS) — a rare & life-threatening pediatric… https://t.co/tY7SjiacMd pic.twitter.com/ZSvEDtg4CY

— Stock Master Flash (@StckMasterFlash) June 11, 2025

[CommodityCoverage]

Backed by orphan drug designation and now entering a Phase 2 clinical trial in Europe, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a breakthrough therapy for a rare pediatric mitochondrial disease that currently has no approved treatment:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

With a seasoned leadership team, and regulatory momentum on its side, TTI is positioning itself at the intersection of rare disease innovation and market opportunity.

[CommodityCoverage]

With a fast-track regulatory path, data expected by fall, and a platform targeting multiple billion-dollar orphan indications, Thiogenesis Therapeutics (TTI.v TTIPF) has officially entered Phase 2 with TTI-0102 for MELAS—a rare, life-altering mitochondrial disease with no approved treatments.
 
Significantly, this positions the company for a major valuation rerate opportunity as it advances one of the most de-risked Phase 2 programs in biotech.
 
More info here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

With a low market cap, a de-risked regulatory path, and a potentially first-in-class treatment, Thiogenesis Therapeutics (TTI.v TTIPF) just marked a major milestone with the dosing of its first patients in a Phase 2 trial for MELAS, a rare and debilitating mitochondrial disease with zero approved therapies worldwide:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

Notably, the MELAS treatment market represents a multibillion-dollar opportunity, with high unmet medical need, orphan drug pricing potential, and virtually no competition in the U.S. or EU.

[CommodityCoverage]

Major milestone for under the radar biotech- Thiogenesis Therapeutics (TTI.v TTIPF) just dosed its first patients in a Phase 2 trial for MELAS—a devastating mitochondrial disease with no approved treatments in the U.S. or EU.
 
Here’s why this could be a rerating moment for the stock:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) has initiated its Phase 2 clinical trial of TTI-0102 for MELAS, a rare mitochondrial disorder with no approved treatments, to evaluate the safety, efficacy, and quality-of-life outcomes over six months:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

With a streamlined 505(b)(2) and EU hybrid regulatory path, interim data expected this fall, and a market valuation well below peers, the trial marks a critical inflection point for TTI.

[CommodityCoverage]

In a biotech landscape filled with early-stage candidates, Thiogenesis Therapeutics (TTI.v TTIPF) is moving forward with a Phase 2 trial for MELAS, a rare mitochondrial disorder with no approved treatments.
 
With orphan drug status, a 505(b)(2) pathway, and supportive clinical precedent, TTI is advancing a targeted approach in a space with limited competition and high unmet need, positioning itself for a potential rerating as results approach.
 
Check out the latest update here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

With first patients now dosed in its Phase 2 trial for MELAS—a rare, life-threatening mitochondrial disease—Thiogenesis Therapeutics (TTI.v TTIPF) is stepping into a major clinical inflection point.
 
Backed by a de-risked regulatory path, orphan drug incentives, and a platform targeting multiple high-value indications, TTI is emerging as a compelling under-the-radar biotech with rerating potential:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) has officially entered Phase 2 with TTI-0102 for MELAS—a rare, devastating mitochondrial disease with no approved treatments in the U.S. or EU:  

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

 
Backed by orphan drug potential, a de-risked regulatory path, and early human data showing strong tolerability, TTI is now on track for a pivotal interim readout this fall—setting the stage for a major valuation inflection.

[CommodityCoverage]

Focused on an addressable market estimated to exceed $1 billion globally, Thiogenesis Therapeutics (TTI.v TTIPF) is a clinical-stage biotech developing breakthrough treatments for mitochondrial diseases — devastating conditions with no approved therapies.

Having just entered a Phase 2 trial for MELAS, a rare genetic disorder that causes progressive neurological decline, TTI is targeting a de-risked regulatory pathway with promising early data, in a market where peer companies trade at valuations 10x higher.

More info here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

Posted on Behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) has initiated dosing in its 12-patient, double-blind Phase 2 clinical trial of TTI-0102 for MELAS to evaluate safety, efficacy, and quality-of-life improvements, with an interim analysis expected by fall 2025.

Backed by a de-risked 505(b)(2)/EU hybrid regulatory pathway, strong Phase 1 tolerability data, and orphan drug potential, TT has a sub-$20M valuation versus peer averages near $250M amid this pivotal clinical phase.

Full Breakdown:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

Posted on Behalf of Thiogenesis Therapeutics Corp.

[StockInfo11]

Thiogenesis (TTI.v TTIPF) recently dosed the first patients in its Phase 2 trial of TTI-0102 for MELAS, a rare mitochondrial disease with no approved drugs. The 6-month, multi-centre study in the EU tests antioxidant-boosting therapy targeting glutathione/taurine deficiency. Full news here: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6826190db73f80b48ac4e635_TTI%20%20NR%2014052025%20MELAS%20Ph2%20Initiation(F)%20.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Targeting a severe mitochondrial disorder with no approved therapies, Thiogenesis Therapeutics (TTI.v TTIPF) dosed the first patients for its Phase 2 trial for TTI-0102 for MELAS
 
With a de-risked regulatory pathway and promising orphan drug potential, this milestone marks a critical step in validating TTI’s platform and positions the company for a potential value re-rating ahead of interim data expected this fall.

Check out the full story here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Last week, Thiogenesis Therapeutics (TTI.v TTIPF) announced the dosing of the first patients in its Phase 2 trial for MELAS, a rare and fatal mitochondrial disease with no approved treatments.

Backed by a fast-track regulatory path, interim data expected by fall, and a de-risked regulatory path in both the EU and U.S., TTI is entering prime rerating territory at a fraction of peer valuations.

Full Breakdown Here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

With its first patients now dosed in a Phase 2 trial for MELAS—a devastating orphan disease with no approved therapies—Thiogenesis Therapeutics (TTI.v TTIPF) is entering rerating territory.

Backed by a de-risked 505(b)(2) regulatory path, a validated mechanism of action, and a platform with multi-billion-dollar potential, TTI’s sub-$20M valuation stands in stark contrast to its Phase 2 biotech peers averaging $249M.

Full Breakdown Here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) has officially entered a pivotal new phase — dosing the first patients in its Phase 2 trial for MELAS, a rare and devastating mitochondrial disease with no approved treatments.

With a streamlined regulatory pathway, European trial stability, and promising early data from TTI-0102,TTI is now on track to deliver interim results in September/October—potentially unlocking valuation upside in one of biotech’s most overlooked orphan disease spaces.

Full Breakdown Here:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[CommodityCoverage]

Today, Clinical-stage biotech company Thiogenesis Therapeutics (TTI.v TTIPF) announced the dosing the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare and debilitating mitochondrial disease.

The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S."

Notably, entry into Phase 2 itself significantly raises company valuations as comparable biotech firms average US$249M in valuation (~15x TTI's current valuation).

For more information, refer to this mews & company breakdown:

TODAY: @thiogenesis Initiates Phase 2 Clinical Trial in MELAS

Clinical-stage biotech company $TTI has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare & debilitating mitochondrial disease.

🧵Company & News Breakdown🔽$TTI.v $TTIPF https://t.co/CqaR4AJVF1

— Stock Master Flash (@StckMasterFlash) May 14, 2025

[StockInfo11]

Thiogenesis (TTI.v TTIPF) has secured final EU approval for its Phase 2 trial of TTI-0102 in MELAS, a rare pediatric disorder. Launching research in Europe offers regulatory stability—an edge as U.S. biotech faces headwinds from policy cuts and political uncertainty.
https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/67b0bfe1bbff5977b54dadd6_TTI-NR%20250127%20MELAS%20CTA%20Clearance%20Final.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

[StockInfo11]

Thiogenesis Therapeutics (TTI.v, TTIPF) has EMA clearance to begin Phase 2 trials in Europe for its drug for MELAS, a rare pediatric mitochondrial disease. The company is also advancing programs in Leigh syndrome and pediatric MASH, targeting major unmet needs in children's health. More: https://thiogenesis.webflow.io

*Posted on behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Marking a major step toward addressing a multibillion-dollar unmet need in oxidative stress-driven disorders, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a next-generation cysteamine prodrug into Phase 2 trials for MELAS—a rare, pediatric mitochondrial disease with no approved therapies.
 
Backed by Phase 1 data showing improved tolerability and guided by biotech veterans from Raptor and BioMarin, TTI is quietly positioning itself for a breakout moment in rare disease therapeutics.

Check out the full story here: https://www.reddit.com/r/Wealthsimple_Penny/comments/1khb61n/thiogenesis_therapeutics_ttiv_ttipf_advances_lead/

[StockInfo11]

Thiogenesis Therapeutics (TTI.v TTIPF) is advancing its lead drug for MELAS to Phase 2 trials in Europe. W/ no approved treatments, MEALS mirrors the market size of Prader-Willi syndrome, where Soleno’s drug helped its stock surge to a $3B+ valuation—highlighting TTI's potential. Full DD here⬇️
https://www.reddit.com/r/Wealthsimple_Penny/comments/1khb61n/thiogenesis_therapeutics_ttiv_ttipf_advances_lead/

[StockInfo11]

Thiogenesis Therapeutics (TTI.v TTIPF) advances TTI-0102 into Phase 2 in Europe for MELAS➡️ https://thiogenesis.webflow.io/investors
With a patient population similar in size to Soleno’s Prader-Willi market, where the approved drug Vykat commands $466K/year and drove a $3B valuation, Thiogenesis targets a comparable rare disease opportunity.
https://www.biopharmadive.com/news/soleno-fda-approval-prader-willi/743563/

*Posted on behalf of Thiogenesis Therapeutics Corp.

[CommodityCoverage]

Clinical-stage biopharmaceutical company, Thiogenesis Therapeutics (TTI.v TTIPF), is developing sulfur-containing prodrugs designed to enhance intracellular antioxidant levels, aiming to treat serious pediatric diseases with unmet medical needs.

It's lead compound, TTI-0102, is engineered to address challenges that have historically limited thiol-based drug development and has demonstrated good tolerability at high doses in human volunteer studies.

With a focus on developing therapies for conditions with significant unmet needs, TTI is positioning itself as a key player in the field of mitochondrial disease treatment.

For more information on TTI, including a comparison to a $3B mcap company, check out the following:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

[CommodityCoverage]

Thiogenesis Therapeutics (TTI.v TTIPF) just secured EMA approval to launch a Phase 2 trial of its lead drug, TTI-0102, targeting MELAS—a devastating pediatric mitochondrial disorder with no approved treatments.
 
As the first sustained-release cysteamine prodrug designed to improve safety, bioavailability, and antioxidant support, TTI-0102 could redefine care for MELAS and unlock broader potential in rare metabolic diseases like Leigh Syndrome and pediatric MASH.
 
More info here: https://www.reddit.com/r/smallstreetbets/comments/1jx3xw3/thiogenesis_therapeutics_ttiv_ttipf_approved_to/

[CommodityCoverage]

Advancing a new class of thiol-based drugs, Thiogenesis Therapeutics (TTI.v TTIPF) is targeting some of the most difficult-to-treat mitochondrial and metabolic disorders—including MELAS, Leigh syndrome, and pediatric fatty liver disease.
 
Leveraging a fast-track 505(b)(2) regulatory pathway and promising Phase 1 data to unlock a scalable, antioxidant-driven therapeutic platform, TTI poised to disrupt high-need pediatric markets with its lead candidate, TTI-0102, which is currently in phase 2 trials.
 
More info here:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

 

[CommodityCoverage]

Targeting high unmet needs with a de-risked path to approval, Thiogenesis Therapeutics (TTI.v TTIPF) is quietly building a breakout opportunity in rare diseases. With a scalable platform, favorable pricing trends, and a growing addressable market, TTI offers asymmetric upside for long-term investors:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

[CommodityCoverage]

Following Soleno Therapeutics’ $3B market cap surge after rare disease FDA approval, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing TTI-0102 during Phase 2 clinical trials as a treatment for MELAS.

With no approved therapies for MELAS, a significant unmet disease, Thiogenesis is positioned to enter a market where recent approvals have demonstrated substantial value creation.

Full breakdown here:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

[CommodityCoverage]

In a field with no approved treatments and devastating impacts on young lives, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing TTI-0102—an innovative therapy designed to restore mitochondrial health and target the root causes of MELAS.

With cytoprotective, antioxidant, and mitochondrial-stabilizing properties, TTI-0102 could address one of the largest unmet needs in rare disease today and replicate Soleno's $3B surge.

Check out the full story here:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

[CommodityCoverage]

Soleno Therapeutics turned a rare disease FDA approval into a $3B surge—jumping from $4 to $72. Now, Thiogenesis Therapeutics (TTI.v TTIPF) is poised to replicate this run with a Phase 2-ready treatment for MELAS and a fast-track regulatory path already in place.

Soleno showed the market what’s possible. Thiogenesis might show what’s next.

Full deep dive:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025

[CommodityCoverage]

Soleno Therapeutics (SLNO) went from $4 to $72—a $3B market cap leap—after delivering in an orphan disease with high unmet need and pricing power. Now, Thiogenesis Therapeutics (TTI.v TTIPF) may be on a similar trajectory.

With a Phase 2-ready therapy targeting MELAS and other mitochondrial disorders—conditions affecting up to 70,000 U.S. patients—and a regulatory path already de-risked through EMA and 505(b)(2) designations, TTI is lining up for potential breakout.

Soleno proved what’s possible. Thiogenesis could prove what’s next. Full deep dive here:

Mitochondrial Focus Could Unlock a Multi-Billion Dollar Opportunity $TTI.v $TTIPF $SLNO

To evaluate @thiogenesis' potential multi-billion opportunity, it’s worth looking at a highly relevant comparison - both from a market dynamics & valuation perspective = Soleno Therapeutics.… https://t.co/lZPrRvUrGn pic.twitter.com/nKf625jJBf

— Stock Master Flash (@StckMasterFlash) April 1, 2025